Original paper

Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours

Duygu İmre Yetkin1A,B,C,D,E,F, Meltem Gulsun Akpınar2A,B,E,F, Gamze Durhan2A,B,E, Figen Basaran Demirkazik2A,B

1Midyat State of Hospital, Midyat/Mardin, Turkey
2Hacettepe University Faculty of Medicine, Ankara, Turkey

Abstract

Purpose: Triple-negative breast cancer (TNBC) has some distinctive features. The aim of the study was to compare clinical and breast magnetic resonance imaging (MRI) findings of TNBC with non-triple-negative breast cancer (nTNBC) in molecular subtypes such as ADC (apparent diffusion coefficient) values, T2-weighted (T2W) image intensity, shape, margin, lymph node involvement, grade, multifocality, multicentricity, bilaterality, and enhancement pattern differences between tumour subtypes.

Material and methods: A total of 141 patients who underwent breast biopsy at our institution between January 2010 and June 2018 were included in this study. Patients were divided into molecular subtypes according to hormone receptor status, and Ki-67 index. Tumour grade, enhancement patterns, age, lymph node involvement, ADC values, breast imaging reporting and data system (BI-RADS) category, bilaterality, multifocality, multicentricity, margin, shape, and T2W image intensity were evaluated for these subtypes.

Results: ADC values were higher in triple-negative tumours than in luminal A and luminal B tumours (p = 0.010 and p = 0.002, respectively). Circumscribed margin, type 2 enhancement curve, and rim enhancement were significantly higher in triple-negative tumours (p < 0.001). No significant difference was found between the groups in terms of other MRI findings including bilaterality, multifocality, multicentricity, shape, and T2W image intensity (p > 0.05).

Conclusions: ADC values, circumscribed margin, and rim enhancement can provide important information about the tumour's biological behaviour and the course of the disease.

Key words: ADC, breast MRI, triple-negative tumours.

Introduction

Breast cancer is the most commonly seen type of cancer in women and a highly heterogeneous cancer with various morphological features, clinical courses, and treatment responses [1]. This diversity leads to the need for a standardized management in the diagnosis and treatment of the disease [2,3]. Immunohistochemical markers, besides the classical parameters such as tumour size, grade, and lymph node involvement, play a considerable role in subtyping the disease, determining prognosis, and selecting the treatment protocol [3-5]. According to the immunohistochemical markers, breast cancer is divided into several subtypes [6]. Triple-negative breast cancer (TNBC) accounts for about 15% of all breast cancer cases and is associated with a poor prognosis and a high ratio of distant recurrence [7-9]. Diagnosis of TNBC and distinction from other subgroups is essential for the treatment to be chosen. However up to 20% of immunohistochemical determinations of estrogen receptors (ER) and progesterone receptors (PR) testing may be inaccurate (false negative or positive). The reason for this difference can be due to variations in pre-analytic variables, positive threshold values, and evaluation criteria [10]. The presence of the features of TNBC
in magnetic resonance imaging (MRI) distinguishing it from non-triple-negative breast cancer (nTNBC) may be cautionary in repetition of pathological specimen assessment if required. This can lead to significant differences in patient management.

Routinely, mammography and breast ultrasound are used in the evaluation of breast cancer. Breast MRI is used to exclude breast cancer or diseases requiring immediate treatment in symptomatic patients, preoperative staging, and treatment selection in patients with known malignancy (surgical or medical treatment, etc.). Breast MRI has the highest sensitivity (83-99%) in detecting breast cancer among imaging modalities [11]. As well as for diagnosis of breast cancer, MRI findings may differentiate breast cancer subtypes.

In this study, we aimed to retrospectively evaluate the differences between TNBC and nTNBC in terms of MRI findings and clinical features. Lesions were classified according to immunohistochemical status. In addition, we aimed to evaluate parameters such as T2W image intensity, margin, size, lymph node involvement, multifocality, multicentricity, contrast enhancement patterns, and their relevance within molecular subtypes.

Material and methods

Patients

Approval for the study was granted by Hacettepe University Faculty of Medicine’s Ethics Commission. Informed consent was not required because of the retrospective nature of the study. 141 of 2546 women who had a biopsy-proven, > 5 mm mass forming invasive breast cancer at our institution between January 2010 and June 2018 were included in this study. The age of the participants was over 18 years. Lesions which were benign, compatible with metastasis or malignant phyllodes tumour, less than 5 mm in size or non-mass forming lesions, patients under 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour, less than 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour were excluded in this study. The age of the participants was over 18 years. Lesions which were benign, compatible with metastasis or malignant phyllodes tumour, less than 5 mm in size or non-mass forming lesions, patients under 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour were excluded in this study. The age of the participants was over 18 years. Lesions which were benign, compatible with metastasis or malignant phyllodes tumour, less than 5 mm in size or non-mass forming lesions, patients under 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour were excluded in this study. The age of the participants was over 18 years. Lesions which were benign, compatible with metastasis or malignant phyllodes tumour, less than 5 mm in size or non-mass forming lesions, patients under 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour were excluded in this study. The age of the participants was over 18 years. Lesions which were benign, compatible with metastasis or malignant phyllodes tumour, less than 5 mm in size or non-mass forming lesions, patients under 18 years of age, patients who underwent chemotherapy and/or surgery before breast MRI, and patients without metastasis or malignant phyllodes tumour were excluded in this study.

Imaging

The MRI scans were acquired with the patient in prone position using a 1.5-Tesla MRI scanner (Signa HD, GE Medical Systems, USA) with a 4-channel phased array breast coil. The imaging protocol included the following sequences: axial T2W fat saturated (TR/TE 5100/90 ms, slice thickness [ST] = 2 mm, flip angle [FA] 90°, matrix 256 × 256), axial echo-planar DWI (TR/TE 4.5/2.1 ms, ST = 2 mm, FA = 10°, matrix 512 × 512) were obtained at intervals of 90 s. Dynamic breast examination was performed after the injection of intravenous contrast material (Dotarem, Guerbet, Roissy, France) through the antecubital vein at a dose of 0.1 mmol/kg using a power injector (Medrad, Bayer HealthCare, Netherlands). After pre-contrast T1-weighted images, the following 5 axial T1-weighted post-contrast dynamic sequences (TR/TE 4.5/2.1 ms, ST = 2 mm, FA = 10°, matrix 512 × 512) were obtained at intervals of 90 s. Patients were evaluated retrospectively by consensus of 2 radiologists. ADC values of the patients were measured by free hand region of interest (ROI) (Figures 1 and 2).

Pathological examination

The pathological examination reports were reviewed to determine histopathological type, tumour grade, and immunohistochemical findings including ER, PR, and HER 2 status. Tumours that were ER positive, HER 2 negative, and with Ki 67 < 14% were defined as luminal A; ER positive, HER 2 positive, and Ki 67 > 14% were defined as luminal B; ER negative and HER 2 positive were defined as Her 2-enriched type; ER, PR, and HER 2 negative were defined as triple negative. The threshold value for ER and PR positivity was 1%, for HER 2 positivity was either 3 positive or 2 positive, and the number of HER 2 gene amplifications in chromosome 17 by fluorescence in situ hybridization (FISH) was more than 2.2 [6]. According to ER, PR, HER2, and ki-67 status the lesions were divided into molecular subtypes (luminal A, luminal B, Her 2-enriched, and triple negative). The parameters described above were evaluated for each patient.

Statistical analysis

The research data were uploaded to the computer via SPSS for Windows 22.0 (SPSS Inc., Chicago, IL) and evaluated. Descriptive statistics were presented as mean ± standard deviation (minimum-maximum), frequency distribution, and percentage. Pearson’s χ² test was used to evaluate categorical variables. The suitability of the variables to normal distribution was examined using visual (histogram and probability graphs) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk test). For the variables that were not found to fit the normal distribution, the Mann-Whitney U test was used for statistical significance between 2 independent groups; for 3 and more independent groups
Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours

**Results**

**Clinical and histopathological findings**

The data of 141 patients were analysed. The mean age was 51.4 ± 10.1 (min 29; max 75) years. 18.4% (n = 26) of the patients were triple negative, 48.9% (n = 69) were luminal B, 22.7% (n = 32) were luminal A, and 11.3% (n = 16) were Her 2-enriched types. 70.9% of the patients were ER+, 63.1% were PR+, and 68.8% were HER 2−. Lymph node involvement was present in 56% of the patients.

Invasive ductal carcinoma was present in 85.1% of the patients, and 88.3% of them had unspecified type of invasive ductal carcinoma (IDC NOS). Mixed infiltrative type carcinoma was detected in 10% of the patients, 79% of which were NOS IDC and lobular carcinoma. Invasive lobular carcinoma was observed in 5% of patients.

MRI features and molecular findings of lesions according to histological grades are shown in detail in Table 1. Lymph node involvement was higher in patients with grade 3 tumours compared to grade 1 and 2. The percentage of grade 3 in triple negative tumours was significantly higher than grade 1 and 2. ER and PR positivity were higher, and HER2 positivity was lower in grade 1 tumours compared to grade 2 and 3 (p < 0.05).

The ratio of grade 1 tumour was higher in luminal A tumours and lower in luminal B tumours (p < 0.05). Axillary lymph node involvement was higher in Her 2-enriched tumours compared to other molecular subtypes and lower in luminal A tumours (p < 0.001).

Neither molecular subtypes nor tumour grades showed any statistically significant difference according to patient’s age.

**Magnetic resonance imaging findings**

The average size of the lesions was 40.1 × 28.6 mm. 33.3% of the lesions were multifocal, 19.1% were multicentric, and 1.4% were bilateral. The margin of the lesions was spiculated in 50.4%, irregular in 48.2%, and circumscribed...
in 1.4% of the cases. The shape of the lesions was irregular in 89.4%, oval in 8.5%, and round in 2.1% of the cases. Irregular margin was found most frequent in Her 2-enriched tumours, spiculated margin was most common in luminal B tumours, and circumscribed margin was most common in triple negative tumours ($p = 0.027$). On T2W images, 44% of the lesions were isointense, 28.3% were hyperintense, and 27.7% were hypointense. The mean ADC value was $1.138 \times 10^{-3}$ mm$^2$/s. 73.8% of the lesions revealed type 3, 21.2% type 2, and 5% type 1 enhancement patterns. According to the BI-RADS classification, 58.2% of the lesions were classified as BI-RADS 5, 34.8% as BI-RADS 6, and 7% as BI-RADS 4.

ADC values of lesions according to molecular subtypes are shown detailed in Table 2. The ADC value of triple negative tumours was higher compared to luminal A and luminal B tumours ($p = 0.010$ and $p = 0.002$, respectively).

Rim enhancement was present in 17.7% of patients. It was most common in triple negative tumours compared to other molecular subtypes ($p < 0.01$). Type 3 enhancement curve was highest in luminal B tumours, type 2 was highest in triple negative tumours, and type 1 was highest in luminal A tumours ($p = 0.018$).

Type 2 and 3 enhancement curves were higher in grade 3 tumours, and type 1 enhancement was higher in grade 1 tumours ($p = 0.029$). No statistically significant difference was found between ADC values, rim enhancement, multifocality, multicentricity, and tumour grade (Table 1).

There was no statistically significant difference found between molecular subtypes in terms of T2 intensity, shape, BI-RADS category, multifocality, and multicentricity ($p > 0.05$ for all) (Table 3).

### Discussion

The most important findings in this study were higher ratio of ADC values, rim enhancement pattern, type 2 enhancement curve, and circumscribed margin features in triple negative tumours compared to other molecular subtypes. On the other hand, T2 intensity, shape, BI-RADS category, multifocality, and multicentricity did not show any significant difference in triple negative lesions.
TNBC constitutes a small portion of all breast cancers, approximately 15-20%; however, it is one of the major causes of breast cancer-related deaths due to the inability to use targeted therapy [12]. Knowing the imaging characteristics of triple negative tumours allows us to predict the biological behaviour of the tumour. In patients with imaging findings suggest a triple negative tumour and in whose pathological report is different from imaging findings, MRI features may play an important role in the changing treatment plan of the patients by enabling the re-evaluation of the pathological specimen.

In our study, the ADC value was higher in triple negative tumours than in luminal A and luminal B tumours. Xie et al. found that the ADC value of triple negative tumours was higher than that of luminal A tumours; however, no difference was found between luminal B and tri-

| Parameter                      | Grade I (n = 13)        | Grade II (n = 60)   | Grade III (n = 68) | p*  |
|--------------------------------|-------------------------|---------------------|-------------------|-----|
| Age (year)                     | 50.2 ± 7.3 (42-67)      | 52.6 ± 10.8 (34-75) | 50.5 ± 9.8 (29-70) | 0.754|
| Lymph node involvement, n (%)  | 4 (30.8)                | 26 (43.3)           | 49 (72.1)         | 0.001|
| Bilaterality, n (%)            | 0                       | 2 (3.3)             | 0                 | 0.531|
| ER(+), n (%)                   | 13 (100)                | 51 (85.0)           | 36 (52.9)         | < 0.001|
| PR(+), n (%)                   | 13 (100)                | 42 (70.0)           | 34 (50.0)         | 0.001|
| Her2Neu(+), n (%)              | 0                       | 20 (33.3)           | 24 (35.3)         | 0.038|
| Triple negative, n (%)         | 0                       | 5 (8.3)             | 19 (27.9)         | 0.003|
| Luminal A, n (%)               | 12 (92.3)               | 20 (33.3)           | 0                 | < 0.001|
| Luminal B, n (%)               | 1 (7.7)                 | 31 (51.7)           | 37 (54.4)         | 0.007|
| Enhancement pattern, n (%)     |                         |                     |                   |     |
| Type 1                         | 3 (23.1)                | 3 (5.0)             | 1 (1.5)           | 0.029|
| Type 2                         | 2 (15.4)                | 13 (21.7)           | 15 (22.1)         |     |
| Type 3                         | 8 (61.5)                | 44 (73.3)           | 52 (76.4)         |     |
| Rim enhancement, n (%)         | 1 (7.7)                 | 10 (16.7)           | 14 (20.6)         | 0.515|
| Multifocality, n (%)           | 6 (46.2)                | 20 (33.3)           | 21 (30.9)         | 0.564|
| Multicentricity, n (%)         | 2 (15.4)                | 7 (11.7)            | 18 (26.5)         | 0.098|
| ADC (< 10⁻³ mm²/s), mean ± SD (minimum-maximum) | 1.139 ± 0.228 (0.821-1.793) | 1.135 ± 0.262 (0.781-2.391) | 1.141 ± 0.258 (0.542-1.676) | 0.893|

MRI – magnetic resonance imaging, ADC – apparent diffusion coefficient. *Kruskal-Wallis test

| Molecular subtype | n/mean ± SD (min-max) | Molecular subtype | n/mean ± SD (min-max) | p-value |
|-------------------|------------------------|-------------------|------------------------|---------|
| Triple (–)*       | 24/1.287 ± 0.271 (0.878-1.870) | Her-2 enriched | 16/1.152 ± 0.216 (0.871-1.624) | 0.145   |
| Triple (–)        | 24/1.287 ± 0.271 (0.878-1.870) | Luminal A         | 32/1.098 ± 0.189 (0.821-1.793) | 0.010   |
| Triple (–)        | 24/1.287 ± 0.271 (0.878-1.870) | Luminal B         | 69/1.102 ± 0.270 (0.542-2.391) | 0.002   |
| Her-2 enriched    | 16/1.152 ± 0.216 (0.871-1.624) | Luminal A         | 32/1.098 ± 0.189 (0.821-1.793) | 0.454   |
| Her-2 enriched    | 16/1.152 ± 0.216 (0.871-1.624) | Luminal B         | 69/1.102 ± 0.270 (0.542-2.391) | 0.345   |
| Luminal A         | 32/1.098 ± 0.189 (0.821-1.793) | Luminal B         | 69/1.102 ± 0.270 (0.542-2.391) | 0.877   |

*Mann-Whitney U test. *Post-hoc binary comparisons. ADC – apparent diffusion coefficient

Table 2. Molecular subtypes and apparent diffusion coefficient (ADC) correlation
ple negative tumours [13]. In the study conducted by Youk et al., regardless of the PR status, in contrast to our study, they found the ADC values of triple negative tumours higher than Her 2-enriched tumours [1]. Rapid growth and developing intra-tumoural necrosis are responsible for higher ADC values [14].

The higher rate of rim enhancement in triple negative tumours was similar to previous data [1,15]. Overexpression of vascular endothelial growth factor and intra-tumoral hypoxia are the cause of rim enhancement, which is a malignancy indicator [15].

We found a type 2 enhancement curve more frequently in the triple negative group. Uematsu et al. found a type 1 curve to be more frequent in triple negative tumours [14], Angelini et al. found no difference in terms of enhancement curves and molecular subtypes [15]. Although the type 3 enhancement curve has been defined for malignant lesions, triple negative tumours can show type 1 and type 2 enhancement curves and may be confused with benign lesions. The contrast enhancement curve alone is misleading in distinguishing triple negative tumours from benign lesions, and other sequences should be carefully evaluated. Circumscribed margin is another misleading and confusing MRI feature of triple negative tumours. Uematsu et al. found circumscribed margin with MRI [14]; Wang et al. found same feature with mammography and ultrasound more frequently in TNBC [16].

The grade 3 tumour ratio was higher and the grade 1 tumour ratio was lower in the triple negative tumours. No grade 1 triple negative tumour was detected, as in the study by Chas et al. [17]. Type 2 and type 3 enhancement curves were more frequently detected in grades 2 and 3 tumours, and type 1 enhancement curve was more frequently detected in grade 1 tumours. This was compatible with previous data [18].

Lymph node involvement was most common in Her 2-enriched tumours and least common in luminal A tumours. Her 2-enriched tumours progress more aggressively compared to luminal A, and the risk of nodal and local recurrence after breast conserving surgery was found

| Parameter                        | Triple negative (n = 24) n (%) | Her-2 enriched (n = 16) n (%) | Luminal A (n = 32) n (%) | Luminal B (n = 69) n (%) |
|----------------------------------|-------------------------------|------------------------------|-------------------------|-------------------------|
| **Enhancement pattern, n (%)**  |                               |                              |                         |                         |
| Type 1                           | 1 (4.2)                       | 0                            | 5 (15.6)                | 1 (1.4)                 |
| Type 2                           | 7 (29.2)                      | 4 (25.0)                     | 9 (28.1)                | 10 (14.5)               |
| Type 3                           | 16 (66.7)                     | 12 (75.0)                    | 18 (56.3)               | 58 (84.1)               |
| Rim enhancement                  | 11 (45.8)                     | 6 (37.5)                     | 2 (6.3)                 | 6 (8.7)                 |
| **Rim enhancement**              |                               |                              |                         | < 0.001                 |
| Multifocality                    | 10 (41.7)                     | 7 (43.8)                     | 12 (37.5)               | 18 (26.1)               |
| Multicentricity                  | 7 (29.2)                      | 5 (31.3)                     | 2 (6.3)                 | 13 (18.8)               |
| T2 intensity                     |                               |                              |                         | 0.089                   |
| Isointense                       | 9 (37.5)                      | 6 (37.5)                     | 19 (59.4)               | 28 (40.6)               |
| Hyperintense                     | 11 (45.8)                     | 6 (37.5)                     | 5 (15.6)                | 18 (26.1)               |
| Hypointense                      | 4 (16.7)                      | 4 (25.0)                     | 8 (25.0)                | 23 (33.3)               |
| **Margin**                       |                               |                              |                         | 0.027                   |
| Non-circumscribed                |                               |                              |                         |                         |
| - Spiculated                     | 8 (33.3)                      | 6 (37.5)                     | 17 (53.1)               | 40 (58.0)               |
| - Irregular                      | 14 (58.3)                     | 10 (62.5)                    | 15 (46.9)               | 29 (42.0)               |
| Circumscribed                    | 2 (8.3)                       | 0                            | 0                       | 0                       |
| Shape                            |                               |                              |                         | 0.453                   |
| Irregular                        | 20 (83.3)                     | 13 (81.3)                    | 31 (96.9)               | 62 (89.9)               |
| Oval                             | 3 (12.5)                      | 3 (18.8)                     | 1 (3.1)                 | 5 (7.2)                 |
| Round                            | 1 (4.2)                       | 0                            | 0                       | 2 (2.9)                 |
| BI-RADS                           |                               |                              |                         |                         |
| IV                               | 1 (4.20)                      | 0                            | 6 (18.8)                | 3 (4.2)                 |
| V                                | 16 (66.7)                     | 9 (56.2)                     | 14 (43.8)               | 43 (62.3)               |
| VI                               | 7 (29.2)                      | 7 (43.8)                     | 12 (37.5)               | 23 (33.3)               |

*Kruskal-Wallis test*
to be similar to triple-negative tumours [19]. This explains
the high rate of lymph node involvement in Her 2-enriched
tumours in our study.

While the majority of malignant breast cancers were
hypointense on T2W TSE images in the study of Kuhl
et al., in our patients the tumours were most commonly
isointense and least commonly hypointense on T2W
images [20]. T2W hyperintensity is highly suggestive of
TNBC due to intra-tumoural necrosis, but we found no
significant difference between T2W intensity and molecu-
lar subtypes. Hasebe et al. suggested that the presence of
fibrotic foci in necrotic circumscribed tumours may be an
indicator of repairment, and the outcome may be different
than without fibrotic foci [21]. In our study, the lack of
difference between the groups in T2W images may be due
to the presence of more fibrotic foci in TNBC tumours.
This may indicate that there are different subtypes of triple
negative tumours. Since there was no follow-up of the pa-

tients in our study, we cannot comment about the patient
outcome and survey.

Multifocal lesions were observed in 33.3% and multi-
centric lesions in 19.1% of the patients. In the study of
Neri et al., the rate of multifocality was 11.3% and the
rate of multicentricity was 5.2%; these rates were very low
compared to our study [22]. The reason for this discrep-
ancy is that in the vast majority of patients with existing
MRI, the indication for breast MRI is local advanced stage
breast cancer, and the evaluation of the response of the
tumour to the treatment before and after neoadjuvant
chemotherapy.

As stated in the study of Choi et al., no relationship
was found between tumour grade and ADC value in our
study [23]. This may be due to TNBCs in the grade 3
group despite higher ADC values.

The retrospective nature of our study and the relatively
low number of patients with triple-negative tumours com-
pared to luminal A and B, the lower number of invasive
lobular and mixed infiltrative cancer compared to invasive
ductal cancer, and no follow-up of patients were the limi-
tations of our study. Another limitation of our study was
the exclusion of the non-mass-forming lesions. Because
these lesions grow with a remaining normal parenchyma
and this normal parenchyma may lead to erroneous re-

sults in ADC measurements, we decided to exclude these
cases. MRI finding of a significant part of patients with
lobular cancer is non mass enhancement. Thus, this may
lead to a lower number of patients with lobular cancer in
our study and inclusion of the patients with lobular cancer
into the BI-RADS 4 category.

Conclusions

Higher ADC values, rim enhancement, and circum-
scribed margin are the distinctive features of TNBC tu-
mours. The distinctive MRI features of TNBC should be
well known. While the typical features of the TNBC tu-
mour on MRI are present, if the pathology report is com-
patible with a different subtype, the pathologist should be
informed of the situation, and the pathological specimen
should be re-evaluated. This is very important to plan the
patient's treatment and may prevent unnecessary targeted
therapies.

Conflict of interest

The authors report no conflict of interest.

References

1. Youk JH, Son EJ, Chung J, et al. Triple-negative invasive breast cancer
   on dynamic contrast-enhanced and diffusion-weighted MR imaging: com-
   parison with other breast cancer subtypes. Eur Radiol 2012; 22:
   1724-1734.
2. Yamamoto Y, Iwase H. Clinicopathological features and treatment
   strategy for triple-negative breast cancer. Int J Clin Oncol 2010; 15:
   341-351.
3. De Ronde JJ, Hannemann J, Halfwerk H, et al. Concordance of clinical
   and molecular breast cancer subtyping in the context of preoperative
   chemotherapy response. Breast Cancer Res Treat 2010; 119: 119-126.
4. Denley H, Pinder SE, Elston CW, et al. Preoperative assessment of
   prognostic factors in breast cancer. J Clin Pathol 2001; 54: 20-24.
5. Montagna E, Bagnardi V, Rotmensz N, et al. Immunohistochemi-
   cally defined subtypes and outcome in occult breast carcinomas with
   axillary presentation. Breast Cancer Res Treat 2011; 129: 867-875.
6. Martinich L, Deantoni V, Bertotto I, et al. Correlations between dif-
   fusion-weighted imaging and breast cancer biomarkers. Eur Radiol
   2012; 22: 1519-1528.
7. Oakman C, Viale G, Di Leo A. Management of triple negative breast
cancer. Breast 2010; 19: 312-321.
8. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:
   clinical features and patterns of recurrence. Clin Cancer Res 2007;
   13: 4429-4434.
9. Haafy BG, Yang Q, Reiss M, et al. Locoregional relapse and distant-
   metastasis in conservatively managed triple negative early-stage breast
cancer. J Clin Oncol 2006; 24: 5652-5657.
10. Hammond ME, Hayes DF, Dowsett M, et al. American Society of
    Clinical Oncology/College of American Pathologists guidelines for
    immunohistochemical testing of estrogen and progesterone receptors
    in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
11. Heywang-Köbrunner SH, Bick U, Bradley WG Jr, et al. International
    investigation of breast MRI: results of a multicentre study (11 sites)
    concerning diagnostic parameters for contrast-enhanced MRI based
    on 519 histopathologically correlated lesions. Eur Radiol 2001; 11:
    531-546.
12. Horvath E, Bañuelos OR, Silva CF, et al. Triple receptor-negative breast cancer. How is it seen on imaging findings? Rev Chil Radiol 2012; 18: 97-106.

13. Xie T, Zhao Q, Fu C, et al. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging. Eur Radiol 2019; 29: 2535-2544.

14. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009; 250: 638-647.

15. Angelini G, Marini C, Iacconi C, et al. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (rTNBC). Clin Imaging 2018; 49: 12-16.

16. Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 2008; 246: 367-375.

17. Chas M, Boivin L, Arbion F, et al. Clinicopathologic predictors of lymph node metastasis in breast cancer patients according to molecular subtype. J Gynecol Obstet Hum Reprod 2018; 47: 9-15.

18. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292: 2735-2742.

19. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.

20. Kuhl CK, Klaschik S, Mielcarek P, et al. Do T2 weighted pulse sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? J Magn Reson Imaging 1999; 9: 187-196.

21. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998; 49: 195-208.

22. Neri A, Marrelli D, Megha T, et al. Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases. BMC Surg 2015; 15: 1.

23. Choi SY, Chang YW, Park HJ, et al. Correlation of the apparent diffusion coefficient values on diffusion-weighted imaging with prognostic factors for breast cancer. Br J Radiol 2012; 85: 474-479.